These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37974160)

  • 21. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011006. PubMed ID: 29683474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
    Loo C; Glozier N; Barton D; Baune BT; Mills NT; Fitzgerald P; Glue P; Sarma S; Galvez-Ortiz V; Hadzi-Pavlovic D; Alonzo A; Dong V; Martin D; Nikolin S; Mitchell PB; Berk M; Carter G; Hackett M; Leyden J; Hood S; Somogyi AA; Lapidus K; Stratton E; Gainsford K; Garg D; Thornton NLR; Fourrier C; Richardson K; Rozakis D; Scaria A; Mihalopoulos C; Chatterton ML; McDonald WM; Boyce P; Holtzheimer PE; Kozel FA; Riva-Posse P; Rodgers A
    Br J Psychiatry; 2023 Dec; 223(6):533-541. PubMed ID: 38108319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.
    Van Leeuwen E; van Driel ML; Horowitz MA; Kendrick T; Donald M; De Sutter AI; Robertson L; Christiaens T
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013495. PubMed ID: 33886130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
    Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder.
    Schwartz OS; Amminger P; Baune BT; Bedi G; Berk M; Cotton SM; Daglas-Georgiou R; Glozier N; Harrison B; Hermens DF; Jennings E; Lagopoulos J; Loo C; Mallawaarachchi S; Martin D; Phelan B; Read N; Rodgers A; Schmaal L; Somogyi AA; Thurston L; Weller A; Davey CG
    Trials; 2023 Oct; 24(1):686. PubMed ID: 37875938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Weston J; Singh J; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neural Correlates of the DEEPP (Anti-suicidal Response to Ketamine in Treatment-Resistant Bipolar Depression) Study: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2023 Jan; 12():e41013. PubMed ID: 36573651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.
    Lee W; Sheehan C; Chye R; Chang S; Bayes A; Loo C; Draper B; Agar MR; Currow DC
    PLoS One; 2023; 18(11):e0290876. PubMed ID: 37963146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
    Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
    J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial.
    Fritz BA; Tellor Pennington BR; Palanca BJA; Schweiger JA; Willie JT; Farber NB
    F1000Res; 2022; 11():510. PubMed ID: 37483552
    [No Abstract]   [Full Text] [Related]  

  • 38. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
    Duffy L; Bacon F; Clarke CS; Donkor Y; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Lewis G; Mangin D; Marston L; Moore M; Nazareth I; Wiles N; Lewis G
    Trials; 2019 Jun; 20(1):319. PubMed ID: 31159856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT.
    Serfaty M; King M; Nazareth I; Moorey S; Aspden T; Tookman A; Mannix K; Gola A; Davis S; Wood J; Jones L
    Health Technol Assess; 2019 May; 23(19):1-106. PubMed ID: 31097078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.